| Deal value | $50M |
|---|---|
| Share of market cap | 9.0% |
Key highlights
- Offering includes 7,785,714 shares of common stock and pre-funded warrants for 6,500,000 shares
- Common stock priced at $3.50 per share with warrants priced at $3.49999
- Estimated net proceeds of $46.7 million after underwriting discounts and expenses
- Closing of the capital raise is scheduled for October 28, 2026
- Leerink Partners, Piper Sandler, and Cantor Fitzgerald serving as joint representatives
What Is the Capital Raise?
Aclaris Therapeutics entered into an underwriting agreement on October 27, 2026, to issue 7,785,714 shares of common stock alongside pre-funded warrants for another 6,500,000 shares. Priced at $3.50 per share, the transaction is led by Leerink Partners, Piper Sandler, and Cantor Fitzgerald. The pre-funded warrants carry a nominal exercise price of $0.00001 and have no expiration date, essentially functioning as equity-equivalent instruments. Gross proceeds are estimated at $50.0 million, resulting in approximately $46.7 million in net capital after underwriting discounts and offering expenses. The transaction is slated to close on October 28, 2026, subject to customary conditions.
Down 4.9% since our story on 27 Oct: $3.79 when we broke it → $3.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.48 |
|---|---|
| 20 Oct | $3.77 |
| 21 Oct | $3.81 |
| 22 Oct | $3.83 |
| 23 Oct | $3.75 |
| 26 Oct | $3.79 |
| 27 Oct | $3.79 |
| 28 Oct | $3.96 |
| 29 Oct | $3.99 |
| 30 Oct | $3.97 |
| 2 Nov | $3.80 |
| 3 Nov | $3.74 |
| 4 Nov | $3.68 |
| 5 Nov | $3.61 |
| 6 Nov | $3.90 |
| 9 Nov | $4.24 |
| 10 Nov | $4.15 |
| 11 Nov | $4.34 |
| 12 Nov | $4.00 |
| 13 Nov | $3.92 |
| 16 Nov | $3.60 |
Use of Proceeds
- Funding general corporate purposes and working capital requirements
- Advancing the clinical development of the company's biopharmaceutical pipeline
- Supporting the planned Phase 2b clinical trial for ATI-052 in eosinophilic esophagitis
- Strengthening the balance sheet to meet projected operational expenses through 2028
Strategic Rationale
The timing of this $50 million raise follows Aclaris's recent clinical roadmap disclosures, specifically the planned initiation of Phase 2b trials for ATI-052 in early 2027. This infusion complements previous at-the-market equity programs and private placements conducted throughout 2024 and 2025, indicating a strategy of continuous capital layering to fund research. By utilizing an underwritten offering instead of relying solely on existing at-the-market facilities, the company secures a guaranteed block of capital in a single window. This immediate liquidity is intended to support upcoming clinical milestones while maintaining a cash runway that management previously projected would last through the end of 2028.
Business Overview
Aclaris Therapeutics is a clinical-stage biopharmaceutical firm based in Wayne, Pennsylvania, focused on developing novel drug candidates for immuno-inflammatory diseases. The company’s research and development efforts target specific kinase pathways to address unmet medical needs in dermatology and immunology. Operating without significant product revenue, Aclaris relies on capital markets and strategic partnerships to fund its investigative pipeline. Its current portfolio includes multiple candidates undergoing clinical evaluation, with value creation driven by trial results and regulatory progress. The company’s structure is typical for the biotechnology sector, where high research costs precede the potential commercialization of therapeutic assets.
| Date | Announcement | Amount |
|---|---|---|
| 06 Aug 2026 | At-the-market equity offering programSource: stocktitan.net | $150.0 Million |
| 11 Mar 2026 | At-the-market sale of common stockSource: investor.aclaristx.com | $20.0 Million |
| 09 Mar 2026 | At-the-market sale of common stockSource: cbonds.com | $39.8 Million |
| 27 Feb 2025 | At-the-market equity offering programSource: SEC filing | $100.0 Million |
| 18 Nov 2024 | Private placement of common stockSource: globenewswire.com | $80.0 Million |
| Share price | $3.79 |
|---|---|
| Market cap | $558M |
| Revenue (annual) | $8M |
| 1-month price change | -26.41% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Aclaris Therapeutics, Inc. announcing an underwritten stock offering.
Track Aclaris Therapeutics, Inc. live
Get the next Aclaris Therapeutics, Inc. SEC filing seconds after it lands.





